- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03107429
Effect of Acetazolamide on Intraocular Pressure After Being in the Trendelenburg Position. (TaPPs)
A Pilot Crossover Study in Healthy Volunteers to Assess the Effect of Acetazolamide on Intraocular Pressure After Being in the Trendelenburg Position.
Perioperative vision loss following laparoscopic colorectal surgery is rare but has been reported. Studies show Trendelenburg positioning during surgery can produce a significant rise in the IOP, and this rise is thought to be a possible factor. Acetazolamide decreases IOP by reducing the formation of aqueous humour.
Aims:
To investigate if acetazolamide reduces the IOP rise resulting from Trendelenburg positioning.
Methods:
A randomised cross-over blinded pilot study. Nine healthy volunteers were randomised to start with the placebo or Acetazolamide with a 5 days' washout period. Baseline IOP was measured on both days. After 1.5 hours of taking the medication, volunteers lay head-down at 17 degrees' for 4 hours and IOP measurements repeated. This reading was subtracted from the baseline to give a 'change in IOP'.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
Laparoscopic (keyhole) bowel surgery often requires positioning patients on the operating table in very steeply angled positions for up to four or more hours. There have been case reports of patients suffering cognitive impairment after surgery with long periods of Trendelenburg (person is lying flat at an incline where their head lies lower than their feet) positioning.
Evidence from other fields of surgery suggests that "head-down" positions can produce a significant rise in the intraocular pressure. Transient vision problems and loss of sight has been reported following surgery is rare instances, including one case after laparoscopic colorectal resection. The cause of this is not fully understood, but rises in intraocular pressure (IOP) has been suggested as a possible factor. This may be particularly relevant in patients who have pre-existing high baseline IOP as a result of glaucoma. Studies looking at the effect of Trendelenburg positioning have shown that there is an increase in IOP. This study is to assess the effect of acetazolamide on the IOP rise after being placed in the Trendelenburg position. Acetazolamide is a carbonic anhydrase inhibitor which is used to treat glaucoma. The drug works by decreasing aqueous humour formation. It can be given as eye drops (but the absorption of this is variable and therefore so is the effect), orally and intravenously. The oral dose can be given as a one off dose or a divided dose. Maximum onset of IOP reduction occurs 2 to 5 hours after taking an oral dose and duration is 6-8 hours.
Aims:
This study aims to investigate the effect of acetazolamide on the IOP rise whilst in the Trendelenburg position.
Experimental protocol and methods:
This will be a pilot randomised crossover study with 9 healthy volunteers recruited and randomised to either Group 1 or Group 2. Group 1 will start with the Control Day; Group 2 will start with the Intervention Day. On the Control Day, a baseline IOP using a Tonopen XL will be taken. They will then be placed in 17 degrees head-down position 2.5hours after a placebo is administered for a minimum of 1 hour and a maximum of 4 hours. Repeat IOP measure will be taken whilst in the Trendelenburg position after 5 minutes, and then every 30 minutes from the start of Trendelenburg position. On the Intervention Day, baseline IOP will be taken, they will then be 500mgs of acetazolamide. After 2.5 hours, the volunteers will then be placed in the Trendelenburg position at 17 degrees for position for a minimum of 1hour and a maximum of 4 hours. Repeat IOP measure will be taken whilst in the Trendelenburg position after 5 minutes, and then every 30 minutes from the start of Trendelenburg position.
Inclusion criteria:
Healthy volunteers, aged 18 and over
Exclusions criteria
Pregnancy Breast Feeding Hepatic impairment Patients with pre-existing conditions affecting IOP regulation eg Glaucoma, previous eye surgery Regular medication affecting IOP Under the age of 18 Refusal to give written informed consent
Measurable endpoints/ statistical power
Primary endpoint: Comparison of IOP pressure before and after being placed in the Trendelenburg position between the two days - Day 1 volunteers will be administered with a placebo before being placed in the Trendelenburg position and Day 2 after acetazolamide has been administered.
Power: Bucci et al compared the effect of oral acetazolamide on IOP on 22 patients. They detected a 3.7mmHg decrease in IOP after 2 hours. Using this study, we powered our study to require 18 patients.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy volunteers aged 18 and over
Exclusion Criteria:
- Pregnancy
- Breast Feeding
- Hepatic impairment
- Patients with pre-existing conditions affecting IOP regulation eg Glaucoma, previous eye surgery
- Regular medication affecting IOP
- Under the age of 18
- Refusal to give written informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Placebo and Trendelenburg Position
Volunteers received placebo medication and placed in Trendelenburg. IOP will be measured. Participants will then be administered with a placebo and after 2.5 hours will be placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes. |
Placebo was a sugar based placebo placed in a capsule.
Other Names:
Placed in Trendelenburg Position
|
Experimental: Acetazolamide and Trendelenburg Position
Volunteer given acetazolomide and placed in Trendelenburg position and IOP measured. IOP will be measured. Participants will then be administered with acetazolamide and after 2.5 hours placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes. |
Placed in Trendelenburg Position
Acetazolamide tablets were placed in capsules to make them look similar to placebo.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of IOP pressure during Trendelenburg position after placebo and acetazolamide at each given time point outlined in methods.
Time Frame: 6 days. 2 Days involved in study (6 hours each) and a minimum of 5 days between study days to allow 'wash-out period' of drug.
|
IOP measurements will be taken at each described time point on both study days and the difference in IOP measurement after acetazolamide will be compared to those after placebo.
|
6 days. 2 Days involved in study (6 hours each) and a minimum of 5 days between study days to allow 'wash-out period' of drug.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Parveen Vitish-Sharma, MRCS MSc, NDDC BRU
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C12022015 SoM NDDC TaPPs
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on IOP
-
Mayo ClinicCompletedAssess Phenylephrine on EVP and IOPUnited States
-
Tel-Aviv Sourasky Medical CenterUnknownIOP Changes Due to Anesthesia (Healthy Patients)Israel
-
Bionode, LLCUnknownUnmedicated IOP Before and After TreatmentCanada
-
Nidek Co. LTD.CompletedIOP Ranges(mmHg): 7 to 16, >16 to <23, and 23 or MoreJapan
-
Mati Therapeutics Inc.CompletedElevated Intraocular Pressure (IOP)United States
-
Danube Pharmaceuticals, Inc.CompletedOcular Hypertension | Glaucoma | Elevated IOPUnited Kingdom
-
Fayoum UniversityCompletedIOP Readings Before and After Accelerated Corneal Collagen Crosslinking (CXL)Egypt
-
Columbia UniversityAmgenCompleted
-
Shaare Zedek Medical CenterUnknownOcular Hypertension | Glaucoma | IOPIsrael
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States